About Homie

Homie Razavi is the founder and managing director at the Center for Disease Analysis (CDA), an organization specializing in studying complex and poorly understood diseases. CDA’s goal is to study and publish data to help educate stakeholders and support decision-making in different countries.

Since 2008, Homie has led a team of epidemiologists and modellers to quantify epidemiology of hepatitis C virus (HCV) and forecast the future impact of HCV disease burden. They have analyzed HCV disease burden in over seventy countries and have helped countries develop national strategies. CDA has been responsible for the development of a number of mathematical models currently used by countries to develop intervention strategies for HCV and HBV:
HCV disease progression
HCV transmission
HCV economic impact
HBV vertical transmission; economic impact
HBV disease progression/treatment; economic impact

In addition, CDA has developed the Polaris Observatory, which collects and reports HCV, HBV and HDV epidemiology, disease burden and treatment rate annually. He has a broad background, which includes basic research, commercial development, portfolio management, and decision analysis. He is also a fellow in the Society of Decision Professionals.

This speaker will be presenting at the following session(s)

  • Strategic direction 4: financing for sustainability


    Day: 3 November

    Time: 09:30

    The first of two plenary sessions on strategic direction 4, which addresses the sustainable financing of hepatitis responses within a whole health systems approach.


    • A strategic approach to financing hepatitis.
      Charles Gore, World Hepatitis Alliance
    • Service delivery models.
      Dr. Jeremy Lauer, World Health Organization
    • Financing for hepatitis within a whole health systems approach - a panel discussion.
      Dr. Jeremy Lauer, World Health Organization
      Dr. David Wilson, World Bank
      Dr. Homie Razavi, Center for Disease Analysis

    Session objective:

    • Discover how to approach hepatitis costing, budgeting and financing in a structured way.
    • Understand how the financing system must match the service delivery model and where there are opportunities for integration.
    • Learn how countries can best approach sustainable financing for hepatitis.
  • Public private partnership to eliminate hepatitis and the role of the civil society

    Side meeting

    Day: 3 November

    Time: 13:00

    A lunchtime roundtable organized by ZeShan Foundation in partnership with EndHEP2030.

    Achieving the 2030 hepatitis elimination goals will require all stakeholders to work together. The objective of this session is to provide a platform for the participants to discuss their needs and what they can offer. All participants will receive a questionnaire prior to the meeting. We will review the responses according to the following categories: Public health organizations (national and international), donors, philanthropic foundations, industries, civil society, and government entities. We will then use a facilitated discussion (with the audience) to explore the types of partnerships that are needed to achieve the elimination target. This session is recommended for all who want to contribute to helping shape future partnerships. Attendance is by invitation only and all attendees are required to RSVP.


    Chair: Dr Homie Razavi, Center for Disease Analysis
    Chair: Wangsheng Li, ZeShan Foundation

    • Assessing the need for working capital.
    • Help with hard currency: Overcoming the fact Central Asian, Cuba and some of very low income countries do not have access to hard currency.
    • Mutual recognition of product registration to promote competition and lower prices.
    • How can pooled procurement will work in countries with a tendering process in place?